董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Timothy Block | 男 | Director | 66 | 29.22万美元 | 未持股 | 2021-08-23 |
| Arnold Lippa | 男 | Director | 74 | 30.17万美元 | 未持股 | 2021-08-23 |
| Thomas Adams | 男 | Director | 78 | 29.67万美元 | 未持股 | 2021-08-23 |
| Robert T. Foster | 男 | Chief Executive Officer, Director | 63 | 277.32万美元 | 未持股 | 2021-08-23 |
| Petrus Wijngaard | 男 | Director | 58 | 10.06万美元 | 未持股 | 2021-08-23 |
| John P. Brancaccio | 男 | Director | 73 | 30.35万美元 | 未持股 | 2021-08-23 |
| Gary S. Jacob | 男 | Director,Chairman of the Board | 74 | 31.08万美元 | 未持股 | 2021-08-23 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Cavan | 男 | Chief Financial Officer | 62 | 176.68万美元 | 未持股 | 2021-08-23 |
| Robert T. Foster | 男 | Chief Executive Officer, Director | 63 | 277.32万美元 | 未持股 | 2021-08-23 |
董事简历
中英对照 | 中文 | 英文- Timothy Block
-
Timothy Block，2013年11月26日起担任本公司董事。他是Drexel大学医学院的微生物学和免疫学教授，是Drexel生物技术和病毒学研究所主任，还是Hepatitis B Foundation HBF和Baruch S. Blumberg Institute（一家致力于通过研究、教育和患者支持来发现乙肝治疗方法和改善他们的生活的全国非盈利性机构，原名为Institute for Hepatitis and Virus Research）的联合创始人和总裁。他还是Pennsylvania生物技术中心的总裁和首席执行官。他一直在医学院院系担任专业研究员超过28年，发表了超过180篇文章，拥有12个美国专利，以及2006年起领导或联合了领导了超过5亿美元的研究资金。他获得的荣誉包括：名誉医学博士学位（Bulgarian医学院）、中央雄鹿商会（Centrals Bucks Chamber of Commerce）的终身成就奖、Daily Intelligencer提名世纪100个最杰出人物之一、美国国家癌症研究所的早期检测研究网络杰出服务认可，以及美国众议院表彰代表“杰出成就”的特别奖。他曾频繁向美国国会和各州立法机构提供证词；曾在U.S. FDA任、以及许多美国国立卫生研究院小组和商业董事会（包括Bristol Myers Squibb Entecavir咨询委员会）任职。2009年，他被American Association for the Advancement of Science （AAAS）任命为当选院士。他在医疗领域乙肝的经验和专业知识，使得他能胜任本公司董事。
Timothy Block has served as a director of our Company since November 26 2013. Dr. Block is Professor of Microbiology and Immunology, Drexel University College of Medicine and Director of its Drexel Institute for Biotechnology and Virology Research, and is also the Co-founder and President of the Hepatitis B Foundation HBF and its Baruch S. Blumberg Institute (formerly called the Institute for Hepatitis and Virus Research). Dr. Block is also President and CEO of the Pennsylvania Biotechnology Center. Dr. Block has been a member of medical school faculties as a professional researcher for more than 28 years, publishing more than 180 papers, 12 U.S. patents, and since 2006 has led or “co-led” more than $50 million in research funding. Honors include an honorary Medical Doctorate (Bulgarian Academy of Medicine); the Lifetime Achievement Award from the Centrals Bucks Chamber of Commerce; named one of the regions 100 Most Outstanding People of the Century by the Daily Intelligencer; Distinguished Service Recognition from the National Cancer Institute’s Early Detection Research Network; and a Special Citation from the U.S. House of Representatives in recognition of “outstanding achievements.” Dr. Block has given frequent testimony to the U.S. Congress and State legislatures; has served on U.S. FDA and numerous NIH panels as well as commercial boards including the Bristol Myers Squibb Entecavir Advisory Board. In 2009 Dr. Block was named an elected Fellow of the American Association for the Advancement of Science (AAAS). - Timothy Block，2013年11月26日起担任本公司董事。他是Drexel大学医学院的微生物学和免疫学教授，是Drexel生物技术和病毒学研究所主任，还是Hepatitis B Foundation HBF和Baruch S. Blumberg Institute（一家致力于通过研究、教育和患者支持来发现乙肝治疗方法和改善他们的生活的全国非盈利性机构，原名为Institute for Hepatitis and Virus Research）的联合创始人和总裁。他还是Pennsylvania生物技术中心的总裁和首席执行官。他一直在医学院院系担任专业研究员超过28年，发表了超过180篇文章，拥有12个美国专利，以及2006年起领导或联合了领导了超过5亿美元的研究资金。他获得的荣誉包括：名誉医学博士学位（Bulgarian医学院）、中央雄鹿商会（Centrals Bucks Chamber of Commerce）的终身成就奖、Daily Intelligencer提名世纪100个最杰出人物之一、美国国家癌症研究所的早期检测研究网络杰出服务认可，以及美国众议院表彰代表“杰出成就”的特别奖。他曾频繁向美国国会和各州立法机构提供证词；曾在U.S. FDA任、以及许多美国国立卫生研究院小组和商业董事会（包括Bristol Myers Squibb Entecavir咨询委员会）任职。2009年，他被American Association for the Advancement of Science （AAAS）任命为当选院士。他在医疗领域乙肝的经验和专业知识，使得他能胜任本公司董事。
- Timothy Block has served as a director of our Company since November 26 2013. Dr. Block is Professor of Microbiology and Immunology, Drexel University College of Medicine and Director of its Drexel Institute for Biotechnology and Virology Research, and is also the Co-founder and President of the Hepatitis B Foundation HBF and its Baruch S. Blumberg Institute (formerly called the Institute for Hepatitis and Virus Research). Dr. Block is also President and CEO of the Pennsylvania Biotechnology Center. Dr. Block has been a member of medical school faculties as a professional researcher for more than 28 years, publishing more than 180 papers, 12 U.S. patents, and since 2006 has led or “co-led” more than $50 million in research funding. Honors include an honorary Medical Doctorate (Bulgarian Academy of Medicine); the Lifetime Achievement Award from the Centrals Bucks Chamber of Commerce; named one of the regions 100 Most Outstanding People of the Century by the Daily Intelligencer; Distinguished Service Recognition from the National Cancer Institute’s Early Detection Research Network; and a Special Citation from the U.S. House of Representatives in recognition of “outstanding achievements.” Dr. Block has given frequent testimony to the U.S. Congress and State legislatures; has served on U.S. FDA and numerous NIH panels as well as commercial boards including the Bristol Myers Squibb Entecavir Advisory Board. In 2009 Dr. Block was named an elected Fellow of the American Association for the Advancement of Science (AAAS).
- Arnold Lippa
-
Arnold Lippa，他是我们公司的董事（2015年11月30日以来）。他一直担任Cortex Pharmaceuticals公司的董事会的执行主席（2013年3月以来），并于2015年8月被任命为首席科学官。此前，他曾担任首席执行官兼总裁。他也是Xintria Pharmaceutical Corporation（他于2006年共同创立的公司）的董事会主席。他是T Morgen Capital LLC（投资和管理公司，专注于生物医药公司的创建和管理）的董事会成员兼创始人。2005年以来，T Morgen Capital LLC一直是重大股权所有者，以及Aurora Capital LLC（生命科学公司，专注于FINRA成员公司）的管理成员，在那里他代理T Morgen Capital LLC担任经理。他于2004年共同创立T Morgen Capital LLC，目前代表T Morgen Capital LLC，担任管理成员，并作为BioCapital Management公司（生命科学基金管理公司，Aurora Capital LLC的附属机构）、Atypical BioVentures Fund（生命科学基金管理基金，Aurora Capital LLC的附属机构）的经理。他曾担任DOV Pharmaceutical, Inc.的创始人，也曾担任董事会主席，以及首席执行官（1995年4月公司创立至2005年）。任职DOV公司之前，他曾共同创立并共同管理一些生命2科学公司，包括Praxis Pharmaceuticals, Inc.（他共同创立的公司，于1985年上市），并担任总裁兼首席运营官（1984年至1987年）。
Arnold Lippa has served as a director of our company since December 3 2015. Dr. Lippa has been Executive Chairman of the Board of RespireRx Pharmaceuticals Inc., since March 2013 and was appointed Chief Scientific Officer in August 2015. Previously, he served as Chief Executive Officer and President. He is also Chairman of the Board of Xintria Pharmaceutical Corporation, which he co-founded in 2006. Dr. Lippa is a Managing Member and founder of T Morgen Capital LLC, which is an investment and management company specializing in the creation and management of biomedical companies. Since 2005 T Morgen Capital has been a significant equity owner and a managing member of Aurora Capital LLC, a life science focused FINRA member firm, where Dr. Lippa represents T Morgen Capital as a Manager. In 2004 Dr. Lippa co-founded and currently is representing T Morgen Capital, a Managing Member, as a Manager of Atypical BioCapital Management LLC and Atypical BioVentures Fund LLC, a life science fund management company and fund, respectively, both of which are affiliates of Aurora Capital. Dr. Lippa was a founder of DOV Pharmaceutical, Inc., and served as Chairman of the Board and Chief Executive Officer from its inception in April 1995 until 2005. Prior to DOV, Dr. Lippa co-founded and co-managed a number of life sciences companies, including Praxis Pharmaceuticals, Inc., which he co-founded and took public in 1985 serving as President and Chief Operating Officer from 1984 until 1987. - Arnold Lippa，他是我们公司的董事（2015年11月30日以来）。他一直担任Cortex Pharmaceuticals公司的董事会的执行主席（2013年3月以来），并于2015年8月被任命为首席科学官。此前，他曾担任首席执行官兼总裁。他也是Xintria Pharmaceutical Corporation（他于2006年共同创立的公司）的董事会主席。他是T Morgen Capital LLC（投资和管理公司，专注于生物医药公司的创建和管理）的董事会成员兼创始人。2005年以来，T Morgen Capital LLC一直是重大股权所有者，以及Aurora Capital LLC（生命科学公司，专注于FINRA成员公司）的管理成员，在那里他代理T Morgen Capital LLC担任经理。他于2004年共同创立T Morgen Capital LLC，目前代表T Morgen Capital LLC，担任管理成员，并作为BioCapital Management公司（生命科学基金管理公司，Aurora Capital LLC的附属机构）、Atypical BioVentures Fund（生命科学基金管理基金，Aurora Capital LLC的附属机构）的经理。他曾担任DOV Pharmaceutical, Inc.的创始人，也曾担任董事会主席，以及首席执行官（1995年4月公司创立至2005年）。任职DOV公司之前，他曾共同创立并共同管理一些生命2科学公司，包括Praxis Pharmaceuticals, Inc.（他共同创立的公司，于1985年上市），并担任总裁兼首席运营官（1984年至1987年）。
- Arnold Lippa has served as a director of our company since December 3 2015. Dr. Lippa has been Executive Chairman of the Board of RespireRx Pharmaceuticals Inc., since March 2013 and was appointed Chief Scientific Officer in August 2015. Previously, he served as Chief Executive Officer and President. He is also Chairman of the Board of Xintria Pharmaceutical Corporation, which he co-founded in 2006. Dr. Lippa is a Managing Member and founder of T Morgen Capital LLC, which is an investment and management company specializing in the creation and management of biomedical companies. Since 2005 T Morgen Capital has been a significant equity owner and a managing member of Aurora Capital LLC, a life science focused FINRA member firm, where Dr. Lippa represents T Morgen Capital as a Manager. In 2004 Dr. Lippa co-founded and currently is representing T Morgen Capital, a Managing Member, as a Manager of Atypical BioCapital Management LLC and Atypical BioVentures Fund LLC, a life science fund management company and fund, respectively, both of which are affiliates of Aurora Capital. Dr. Lippa was a founder of DOV Pharmaceutical, Inc., and served as Chairman of the Board and Chief Executive Officer from its inception in April 1995 until 2005. Prior to DOV, Dr. Lippa co-founded and co-managed a number of life sciences companies, including Praxis Pharmaceuticals, Inc., which he co-founded and took public in 1985 serving as President and Chief Operating Officer from 1984 until 1987.
- Thomas Adams
-
Thomas Adams，他是我们公司的董事（2016年9月以来）。他一直担任Trovagene, Inc（分子诊断公司）的董事会主席（2009年4月以来）。他曾担任Clearbridge BioPhotonics, Inc（一个成像解决方案公司）的主席（2013年4月以来）。2005年6月至2011年，他曾担任IRIS International, Inc（诊断公司）的董事，也曾担任IRIS公司的首席技术官（2006年4月以来）。他曾担任Iris Molecular Diagnostics的主席（2006年至2012年11月），也曾担任Iris Personalized Medicine总裁（2011年以来）。IRIS公司于2012年11月被Danaher Corporation收购。他曾担任Leucadia Technologies（私营医疗设备公司）的主席兼首席执行官（1998年至2006年4月Leucadia公司被IRIS收购）。他于1989年创立Genta, Inc（公众持有的反义技术领域的生物科技公司），也曾担任其首席执行官（直到1997年）。他于1984年创立Gen-Probe, Inc.公司，也曾担任其首席执行官兼主席（直到1989年公司被Chugai Biopharmaceuticals, Inc收购）。他曾担任Synergy Pharmaceuticals Inc（一个生物科技公司）的董事（2009年7月以来）。他持有加州大学河滨分校（the University of California, at Riverside）的生物化学博士学位。
Thomas Adams has served as a director of our Company since September 2016. Dr. Adams served as Chairman of the Board of Cardiff Oncology, Inc. from April 2009 until April 2020 Executive Chairman from April 2020 to December 2020 and director since April 2009. Dr. Adams also served as Chief Executive Officer of Cardiff from June 2018 until April 2020 and interim Chief Executive Officer from March 2016 until April 2016. Dr. Adams has served as the Chairman of Clearbridge BioPhotonics, Inc., an imaging solutions company, since April 2013 and as Director of Synergy Pharmaceuticals, Inc. from 2009 to 2019. From June 2005 through 2011 Dr. Adams served as a director of IRIS International, Inc., a diagnostics company, and has served as Chief Technology Officer of IRIS since April 2006. Dr. Adams was the Head of Iris Molecular Diagnostics from 2006 until November 2012 and has served as the President of Iris Personalized Medicine since 2011. In November 2012 IRIS was acquired by Danaher Corporation. Dr. Adams served as Chairman and Chief Executive Officer of Leucadia Technologies, a privately held medical-device company, from 1998 to April 2006 when Leucadia was acquired by IRIS. In 1989 Dr. Adams founded Genta, Inc., a publicly held biotechnology company in the field of antisense technology, and served as its Chief Executive Officer until 1997. Dr. Adams founded Gen-Probe, Inc. in 1984 and served as its Chief Executive Officer and Chairman until its acquisition by Chugai Biopharmaceuticals, Inc. in 1989. Dr. Adams holds a Ph.D. in Biochemistry from the University of California, at Riverside. - Thomas Adams，他是我们公司的董事（2016年9月以来）。他一直担任Trovagene, Inc（分子诊断公司）的董事会主席（2009年4月以来）。他曾担任Clearbridge BioPhotonics, Inc（一个成像解决方案公司）的主席（2013年4月以来）。2005年6月至2011年，他曾担任IRIS International, Inc（诊断公司）的董事，也曾担任IRIS公司的首席技术官（2006年4月以来）。他曾担任Iris Molecular Diagnostics的主席（2006年至2012年11月），也曾担任Iris Personalized Medicine总裁（2011年以来）。IRIS公司于2012年11月被Danaher Corporation收购。他曾担任Leucadia Technologies（私营医疗设备公司）的主席兼首席执行官（1998年至2006年4月Leucadia公司被IRIS收购）。他于1989年创立Genta, Inc（公众持有的反义技术领域的生物科技公司），也曾担任其首席执行官（直到1997年）。他于1984年创立Gen-Probe, Inc.公司，也曾担任其首席执行官兼主席（直到1989年公司被Chugai Biopharmaceuticals, Inc收购）。他曾担任Synergy Pharmaceuticals Inc（一个生物科技公司）的董事（2009年7月以来）。他持有加州大学河滨分校（the University of California, at Riverside）的生物化学博士学位。
- Thomas Adams has served as a director of our Company since September 2016. Dr. Adams served as Chairman of the Board of Cardiff Oncology, Inc. from April 2009 until April 2020 Executive Chairman from April 2020 to December 2020 and director since April 2009. Dr. Adams also served as Chief Executive Officer of Cardiff from June 2018 until April 2020 and interim Chief Executive Officer from March 2016 until April 2016. Dr. Adams has served as the Chairman of Clearbridge BioPhotonics, Inc., an imaging solutions company, since April 2013 and as Director of Synergy Pharmaceuticals, Inc. from 2009 to 2019. From June 2005 through 2011 Dr. Adams served as a director of IRIS International, Inc., a diagnostics company, and has served as Chief Technology Officer of IRIS since April 2006. Dr. Adams was the Head of Iris Molecular Diagnostics from 2006 until November 2012 and has served as the President of Iris Personalized Medicine since 2011. In November 2012 IRIS was acquired by Danaher Corporation. Dr. Adams served as Chairman and Chief Executive Officer of Leucadia Technologies, a privately held medical-device company, from 1998 to April 2006 when Leucadia was acquired by IRIS. In 1989 Dr. Adams founded Genta, Inc., a publicly held biotechnology company in the field of antisense technology, and served as its Chief Executive Officer until 1997. Dr. Adams founded Gen-Probe, Inc. in 1984 and served as its Chief Executive Officer and Chairman until its acquisition by Chugai Biopharmaceuticals, Inc. in 1989. Dr. Adams holds a Ph.D. in Biochemistry from the University of California, at Riverside.
- Robert T. Foster
-
Robert T. Foster， 2016年6月10日以来，他一直担任我们的首席科学官。任职ContraVir公司之前，他曾担任Ciclofilin Pharmaceuticals Inc的首席执行官兼创始人（2014年1月至2016年6月10日公司与ContraVir公司合并）。任职Ciclofilin Pharmaceuticals公司之前，他曾于1993年创立Isotechnika Pharma Inc，在那里他曾担任主席兼首席执行官21年。他曾担任Aurinia Pharmaceuticals, Inc（后被Isotechnika公司收购）的创始首席执行官，随后担任首席科学官。他目前是Transcriptome Sciences Inc的董事会成员。
Robert T. Foster has served as Chief Executive Officer since October 3 2018 and as our Chief Scientific Officer since June 10 2016. Prior to Hepion, he was Chief Executive Officer and Founder of Ciclofilin Pharmaceuticals Inc. from January 2014 until it merged with us on June 10 2016. Prior to Ciclofilin Pharmaceuticals, he founded Isotechnika Pharma Inc. in 1993 where he was Chairman and Chief Executive Officer for 21 years. Dr. Foster was founding Chief Executive Officer and later, Chief Scientific Officer of Aurinia Pharmaceuticals, Inc., after Isotechnika acquired Aurinia. Dr. Foster is currently a Board member of Transcriptome Sciences Inc. - Robert T. Foster， 2016年6月10日以来，他一直担任我们的首席科学官。任职ContraVir公司之前，他曾担任Ciclofilin Pharmaceuticals Inc的首席执行官兼创始人（2014年1月至2016年6月10日公司与ContraVir公司合并）。任职Ciclofilin Pharmaceuticals公司之前，他曾于1993年创立Isotechnika Pharma Inc，在那里他曾担任主席兼首席执行官21年。他曾担任Aurinia Pharmaceuticals, Inc（后被Isotechnika公司收购）的创始首席执行官，随后担任首席科学官。他目前是Transcriptome Sciences Inc的董事会成员。
- Robert T. Foster has served as Chief Executive Officer since October 3 2018 and as our Chief Scientific Officer since June 10 2016. Prior to Hepion, he was Chief Executive Officer and Founder of Ciclofilin Pharmaceuticals Inc. from January 2014 until it merged with us on June 10 2016. Prior to Ciclofilin Pharmaceuticals, he founded Isotechnika Pharma Inc. in 1993 where he was Chairman and Chief Executive Officer for 21 years. Dr. Foster was founding Chief Executive Officer and later, Chief Scientific Officer of Aurinia Pharmaceuticals, Inc., after Isotechnika acquired Aurinia. Dr. Foster is currently a Board member of Transcriptome Sciences Inc.
- Petrus Wijngaard
-
Petrus Wijngaard自2020年6月10日起担任我们公司的董事。Wijngaard博士最近担任The Medicines Company“；MDCO”；的执行副总裁兼首席发展官，在那里他领导了Inclisiran的高胆固醇血症候选药物的整体开发和全球医疗事务活动。韦恩加德博士在诺华公司以97亿美元收购MDCO的交易中发挥了重要作用，该交易于2020年1月完成。此前，Wijngaard博士曾领导Viropharma Inc.（后来于2013年被Shire Pharmaceuticals收购，现在是Takeda Pharmaceutical Company Limited的一部分）的欧洲医疗事务和开发，并在Hoffmann-La Roche担任多个职位，包括移植投资组合的国际医疗经理和生命周期负责人，以及作为全球联盟总监管理基因泰克联盟。他曾任职Isotechnika Pharmaceuticals、Aurinia Pharmaceuticals和Ciclofilin Pharmaceuticals的董事会，后者于2016年被Hepion收购。作为50多篇科学论文的作者，Wijngaard博士在移植免疫学和免疫抑制方面发表了大量的论文。他拥有荷兰乌得勒支大学移植免疫学博士学位。
Petrus Wijngaard has served as a director of our company since June 10 2020. Dr. Wijngaard most recently served as Executive Vice President, Chief Development Officer at The Medicines Company “MDCO”, where he led the overall development and global medical affairs activities for hypercholesterolemia drug candidate, inclisiran. Dr. Wijngaard was instrumental in Novartis’ US $9.7 billion acquisition of MDCO that was completed in January 2020. Previously, Dr. Wijngaard led European Medical Affairs and Development at Viropharma Inc. (which was subsequently acquired by Shire Pharmaceuticals in 2013 and is now part of The Takeda Pharmaceutical Company Limited) and held various positions at Hoffmann-La Roche, including International Medical Manager and Lifecycle Leader for the transplantation portfolio, as well as managing the Genentech alliance as Global Alliance Director. He served on the Board of Directors of Isotechnika Pharmaceuticals, Aurinia Pharmaceuticals and Ciclofilin Pharmaceuticals, which was acquired by Hepion in 2016. - Petrus Wijngaard自2020年6月10日起担任我们公司的董事。Wijngaard博士最近担任The Medicines Company“；MDCO”；的执行副总裁兼首席发展官，在那里他领导了Inclisiran的高胆固醇血症候选药物的整体开发和全球医疗事务活动。韦恩加德博士在诺华公司以97亿美元收购MDCO的交易中发挥了重要作用，该交易于2020年1月完成。此前，Wijngaard博士曾领导Viropharma Inc.（后来于2013年被Shire Pharmaceuticals收购，现在是Takeda Pharmaceutical Company Limited的一部分）的欧洲医疗事务和开发，并在Hoffmann-La Roche担任多个职位，包括移植投资组合的国际医疗经理和生命周期负责人，以及作为全球联盟总监管理基因泰克联盟。他曾任职Isotechnika Pharmaceuticals、Aurinia Pharmaceuticals和Ciclofilin Pharmaceuticals的董事会，后者于2016年被Hepion收购。作为50多篇科学论文的作者，Wijngaard博士在移植免疫学和免疫抑制方面发表了大量的论文。他拥有荷兰乌得勒支大学移植免疫学博士学位。
- Petrus Wijngaard has served as a director of our company since June 10 2020. Dr. Wijngaard most recently served as Executive Vice President, Chief Development Officer at The Medicines Company “MDCO”, where he led the overall development and global medical affairs activities for hypercholesterolemia drug candidate, inclisiran. Dr. Wijngaard was instrumental in Novartis’ US $9.7 billion acquisition of MDCO that was completed in January 2020. Previously, Dr. Wijngaard led European Medical Affairs and Development at Viropharma Inc. (which was subsequently acquired by Shire Pharmaceuticals in 2013 and is now part of The Takeda Pharmaceutical Company Limited) and held various positions at Hoffmann-La Roche, including International Medical Manager and Lifecycle Leader for the transplantation portfolio, as well as managing the Genentech alliance as Global Alliance Director. He served on the Board of Directors of Isotechnika Pharmaceuticals, Aurinia Pharmaceuticals and Ciclofilin Pharmaceuticals, which was acquired by Hepion in 2016.
- John P. Brancaccio
-
John P. Brancaccio，已退休的注册会计师；2005年12月起，担任本公司董事。他从2004年4月起，担任Accelerated Technologies的首席财务官，这是医疗器械公司的孵化器。他目前是Tamir Biotechnology（原Alfacell Corporation）、Synergy Pharmaceuticals、ContraVir Pharmaceuticals（Synergy的子公司）的董事。
John P. Brancaccio a retired CPA, has served as a director of our Company since May 15 2013. Mr. Brancaccio was the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies from April 2004 until May 2017. Mr. Brancaccio served as a director for Callisto Pharmaceuticals, Inc. from April 2004 until its merger with Synergy Pharmaceuticals, Inc. in January 2013 and was formerly a director of Tamir Biotechnology, Inc. formerly Alfacell Corporation since April 2004 until May 2020. He is also a director of Cardiff Oncology, Inc. since December 2005 Rasna Therapeutics, Inc. since September 2016 OKYO Pharma Limited since June 2020 and Tiziana Life Sciences plc since July 2020. Mr. Brancaccio served as a director of Synergy from July 2008 until April 2019. - John P. Brancaccio，已退休的注册会计师；2005年12月起，担任本公司董事。他从2004年4月起，担任Accelerated Technologies的首席财务官，这是医疗器械公司的孵化器。他目前是Tamir Biotechnology（原Alfacell Corporation）、Synergy Pharmaceuticals、ContraVir Pharmaceuticals（Synergy的子公司）的董事。
- John P. Brancaccio a retired CPA, has served as a director of our Company since May 15 2013. Mr. Brancaccio was the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies from April 2004 until May 2017. Mr. Brancaccio served as a director for Callisto Pharmaceuticals, Inc. from April 2004 until its merger with Synergy Pharmaceuticals, Inc. in January 2013 and was formerly a director of Tamir Biotechnology, Inc. formerly Alfacell Corporation since April 2004 until May 2020. He is also a director of Cardiff Oncology, Inc. since December 2005 Rasna Therapeutics, Inc. since September 2016 OKYO Pharma Limited since June 2020 and Tiziana Life Sciences plc since July 2020. Mr. Brancaccio served as a director of Synergy from July 2008 until April 2019.
- Gary S. Jacob
-
Gary S. Jacob。 Gary S. Jacob博士自2009年2月起担任公司董事。自2008年7月以来，Jacob博士一直担任Synergy Pharmaceuticals Inc.的总裁，首席执行官和董事，并担任该公司的董事。 主席自2013年9月起。雅各布博士自2013年5月起担任ContraVir Pharmaceuticals，Inc。的董事长。雅各博士于2004年10月起担任Callisto Pharmaceuticals，Inc。的董事，直至2013年1月与Synergy Pharmaceuticals，Inc。合并。 1999年之前，Jacob博士担任孟山都科学研究员，专攻糖生物学领域，1997年至1998年，他担任孟山都公司的功能基因组学，企业科学与技术总监。 雅各博士获得了B.S。 在密苏里大学化学，并拥有博士学位。 来自威斯康星大学麦迪逊分校的生物化学专业。
Gary S. Jacob has served as our Chairman of the Board since March 19 2014 and earlier served as our Chief Executive Officer from May 15 2013 until March 19 2014. Dr. Jacob has served as Chief Executive Officer and a director of OKYO Pharma Ltd. since January 2021. From November 2018 until March 2020 Dr. Jacob served as Chief Executive Officer of Immuron Limited, an Australian microbiome biopharmaceutical company. Previously, Dr. Jacob was the Chairman of the Board, President and Chief Executive Officer of Synergy Pharmaceuticals Inc., a biopharmaceutical company, where he held various positions from July 2008 to October 2018. On December 12 2018 Synergy Pharmaceuticals Inc. filed a petition for relief under Chapter 11 of the U.S. Bankruptcy Code. Dr. Jacob served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013 and a director from October 2004 until January 2013. Dr. Jacob currently serves as a director of Cardiff Oncology, Inc., a clinical-stage oncology therapeutics company. Dr. Jacob also serves as a director of Virpax Pharmaceuticals, Inc. and Rasna Therapeutics, Inc. Dr. Jacob has over twenty-five years of experience in the pharmaceutical and biotechnology industries across multiple disciplines including research & development, operations and business development. Prior to 1999 Dr. Jacob served as a Monsanto Science Fellow, specializing in the field of glycobiology, and from 1997 to 1998 was Director of Functional Genomics, Corporate Science & Technology, at Monsanto Company. Dr. Jacob also served from 1990 to 1997 as Director of Glycobiology at G.D. Searle Pharmaceuticals Inc. During the period of 1986 to 1990 he was Manager of the G.D. Searle Glycobiology Group at Oxford University, England. - Gary S. Jacob。 Gary S. Jacob博士自2009年2月起担任公司董事。自2008年7月以来，Jacob博士一直担任Synergy Pharmaceuticals Inc.的总裁，首席执行官和董事，并担任该公司的董事。 主席自2013年9月起。雅各布博士自2013年5月起担任ContraVir Pharmaceuticals，Inc。的董事长。雅各博士于2004年10月起担任Callisto Pharmaceuticals，Inc。的董事，直至2013年1月与Synergy Pharmaceuticals，Inc。合并。 1999年之前，Jacob博士担任孟山都科学研究员，专攻糖生物学领域，1997年至1998年，他担任孟山都公司的功能基因组学，企业科学与技术总监。 雅各博士获得了B.S。 在密苏里大学化学，并拥有博士学位。 来自威斯康星大学麦迪逊分校的生物化学专业。
- Gary S. Jacob has served as our Chairman of the Board since March 19 2014 and earlier served as our Chief Executive Officer from May 15 2013 until March 19 2014. Dr. Jacob has served as Chief Executive Officer and a director of OKYO Pharma Ltd. since January 2021. From November 2018 until March 2020 Dr. Jacob served as Chief Executive Officer of Immuron Limited, an Australian microbiome biopharmaceutical company. Previously, Dr. Jacob was the Chairman of the Board, President and Chief Executive Officer of Synergy Pharmaceuticals Inc., a biopharmaceutical company, where he held various positions from July 2008 to October 2018. On December 12 2018 Synergy Pharmaceuticals Inc. filed a petition for relief under Chapter 11 of the U.S. Bankruptcy Code. Dr. Jacob served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013 and a director from October 2004 until January 2013. Dr. Jacob currently serves as a director of Cardiff Oncology, Inc., a clinical-stage oncology therapeutics company. Dr. Jacob also serves as a director of Virpax Pharmaceuticals, Inc. and Rasna Therapeutics, Inc. Dr. Jacob has over twenty-five years of experience in the pharmaceutical and biotechnology industries across multiple disciplines including research & development, operations and business development. Prior to 1999 Dr. Jacob served as a Monsanto Science Fellow, specializing in the field of glycobiology, and from 1997 to 1998 was Director of Functional Genomics, Corporate Science & Technology, at Monsanto Company. Dr. Jacob also served from 1990 to 1997 as Director of Glycobiology at G.D. Searle Pharmaceuticals Inc. During the period of 1986 to 1990 he was Manager of the G.D. Searle Glycobiology Group at Oxford University, England.
高管简历
中英对照 | 中文 | 英文- John Cavan
John Cavan，2016年4月1日以来，他一直担任我们的首席财务官。从2016年1月到2016年4月，他曾担任临时首席财务官。加入ContraVir公司之前，他曾担任The Pine Hill Group的顾问（2012年2月至2016年3月），在那里他曾协助完成多个战略和金融交易，包括首次公开发行、业务组合和战略事务。任职the Pine Hill Group之前，他曾担任Stemline Therapeutics, Inc的首席会计官，以及Aegerion Pharmaceuticals, Inc的副总裁兼首席会计官，在那里他曾协助公司的首次公开发行，通过Aegerion取得了20亿美元的市值（2006年6月至2012年2月）。他也曾担任医疗健康行业的财务职务，任职于 AlgoRx Pharmaceuticals, Inc.、Alpharma。职业生涯早期，他曾担任多种财务和运营职务，任职于大型跨国上市公司，其中包括Sony、American Express、International Specialty Products（Ashland Company）、Nestlé U.S.A.。他目前任职于Vantage Health Systems的董事会。
John Cavan has been our Chief Financial Officer since March 2016. Previously, Mr. Cavan was a consultant with The Pine Hill Group where he was instrumental in completing several financial transactions, including initial public offerings, business combinations and strategic transactions. Prior to his role with the Pine Hill Group, he served as Chief Accounting Officer at Stemline Therapeutics, Inc. Preceding his role at Stemline, Mr. Cavan was Vice President and Chief Accounting Officer at Aegerion Pharmaceuticals, Inc. He has also held financial positions within the healthcare industry at AlgoRx Pharmaceuticals, Inc. and Alpharma. Mr. Cavan served in a variety of financial and operational positions early in his career during tenures with large multinational public companies, including Sony, American Express, International Specialty Products an Ashland Company and Nestlé U.S.A. Mr. Cavan currently serves on the Board of Directors of Vantage Health Systems. He holds a B.B.A in Accountancy from Iona College and an M.B.A. in Finance from Seton Hall University.- John Cavan，2016年4月1日以来，他一直担任我们的首席财务官。从2016年1月到2016年4月，他曾担任临时首席财务官。加入ContraVir公司之前，他曾担任The Pine Hill Group的顾问（2012年2月至2016年3月），在那里他曾协助完成多个战略和金融交易，包括首次公开发行、业务组合和战略事务。任职the Pine Hill Group之前，他曾担任Stemline Therapeutics, Inc的首席会计官，以及Aegerion Pharmaceuticals, Inc的副总裁兼首席会计官，在那里他曾协助公司的首次公开发行，通过Aegerion取得了20亿美元的市值（2006年6月至2012年2月）。他也曾担任医疗健康行业的财务职务，任职于 AlgoRx Pharmaceuticals, Inc.、Alpharma。职业生涯早期，他曾担任多种财务和运营职务，任职于大型跨国上市公司，其中包括Sony、American Express、International Specialty Products（Ashland Company）、Nestlé U.S.A.。他目前任职于Vantage Health Systems的董事会。
- John Cavan has been our Chief Financial Officer since March 2016. Previously, Mr. Cavan was a consultant with The Pine Hill Group where he was instrumental in completing several financial transactions, including initial public offerings, business combinations and strategic transactions. Prior to his role with the Pine Hill Group, he served as Chief Accounting Officer at Stemline Therapeutics, Inc. Preceding his role at Stemline, Mr. Cavan was Vice President and Chief Accounting Officer at Aegerion Pharmaceuticals, Inc. He has also held financial positions within the healthcare industry at AlgoRx Pharmaceuticals, Inc. and Alpharma. Mr. Cavan served in a variety of financial and operational positions early in his career during tenures with large multinational public companies, including Sony, American Express, International Specialty Products an Ashland Company and Nestlé U.S.A. Mr. Cavan currently serves on the Board of Directors of Vantage Health Systems. He holds a B.B.A in Accountancy from Iona College and an M.B.A. in Finance from Seton Hall University.
- Robert T. Foster
Robert T. Foster， 2016年6月10日以来，他一直担任我们的首席科学官。任职ContraVir公司之前，他曾担任Ciclofilin Pharmaceuticals Inc的首席执行官兼创始人（2014年1月至2016年6月10日公司与ContraVir公司合并）。任职Ciclofilin Pharmaceuticals公司之前，他曾于1993年创立Isotechnika Pharma Inc，在那里他曾担任主席兼首席执行官21年。他曾担任Aurinia Pharmaceuticals, Inc（后被Isotechnika公司收购）的创始首席执行官，随后担任首席科学官。他目前是Transcriptome Sciences Inc的董事会成员。
Robert T. Foster has served as Chief Executive Officer since October 3 2018 and as our Chief Scientific Officer since June 10 2016. Prior to Hepion, he was Chief Executive Officer and Founder of Ciclofilin Pharmaceuticals Inc. from January 2014 until it merged with us on June 10 2016. Prior to Ciclofilin Pharmaceuticals, he founded Isotechnika Pharma Inc. in 1993 where he was Chairman and Chief Executive Officer for 21 years. Dr. Foster was founding Chief Executive Officer and later, Chief Scientific Officer of Aurinia Pharmaceuticals, Inc., after Isotechnika acquired Aurinia. Dr. Foster is currently a Board member of Transcriptome Sciences Inc.- Robert T. Foster， 2016年6月10日以来，他一直担任我们的首席科学官。任职ContraVir公司之前，他曾担任Ciclofilin Pharmaceuticals Inc的首席执行官兼创始人（2014年1月至2016年6月10日公司与ContraVir公司合并）。任职Ciclofilin Pharmaceuticals公司之前，他曾于1993年创立Isotechnika Pharma Inc，在那里他曾担任主席兼首席执行官21年。他曾担任Aurinia Pharmaceuticals, Inc（后被Isotechnika公司收购）的创始首席执行官，随后担任首席科学官。他目前是Transcriptome Sciences Inc的董事会成员。
- Robert T. Foster has served as Chief Executive Officer since October 3 2018 and as our Chief Scientific Officer since June 10 2016. Prior to Hepion, he was Chief Executive Officer and Founder of Ciclofilin Pharmaceuticals Inc. from January 2014 until it merged with us on June 10 2016. Prior to Ciclofilin Pharmaceuticals, he founded Isotechnika Pharma Inc. in 1993 where he was Chairman and Chief Executive Officer for 21 years. Dr. Foster was founding Chief Executive Officer and later, Chief Scientific Officer of Aurinia Pharmaceuticals, Inc., after Isotechnika acquired Aurinia. Dr. Foster is currently a Board member of Transcriptome Sciences Inc.